TGTX Other Liab from 2010 to 2024

TGTX Stock  USD 34.61  0.46  1.31%   
TG Therapeutics Other Liabilities yearly trend continues to be fairly stable with very little volatility. Other Liabilities will likely drop to about 260.8 K in 2024. During the period from 2010 to 2024, TG Therapeutics Other Liabilities regression line of annual values had r-squared of  0 and arithmetic mean of  2,525,667. View All Fundamentals
 
Other Liabilities  
First Reported
2008-06-30
Previous Quarter
343 K
Current Value
305 K
Quarterly Volatility
2.8 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check TG Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TG Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 444.1 K, Interest Expense of 13.2 M or Total Revenue of 245.3 M, as well as many indicators such as Price To Sales Ratio of 9.86, Dividend Yield of 4.0E-4 or PTB Ratio of 15.86. TGTX financial statements analysis is a perfect complement when working with TG Therapeutics Valuation or Volatility modules.
  
Check out the analysis of TG Therapeutics Correlation against competitors.
For more information on how to buy TGTX Stock please use our How to Invest in TG Therapeutics guide.

Latest TG Therapeutics' Other Liab Growth Pattern

Below is the plot of the Other Liab of TG Therapeutics over the last few years. It is TG Therapeutics' Other Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TG Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Other Liab10 Years Trend
Very volatile
   Other Liab   
       Timeline  

TGTX Other Liab Regression Statistics

Arithmetic Mean2,525,667
Geometric Mean1,126,183
Coefficient Of Variation202.14
Mean Deviation2,485,289
Median1,371,429
Standard Deviation5,105,418
Sample Variance26.1T
Range20.5M
R-Value(0.06)
Mean Square Error28T
R-Squared0
Significance0.83
Slope(67,845)
Total Sum of Squares364.9T

TGTX Other Liab History

2024260.8 K
2023274.5 K
2022305 K
2021457 K
2020610 K
2019762 K
201820.7 M

About TG Therapeutics Financial Statements

TG Therapeutics investors use historical fundamental indicators, such as TG Therapeutics' Other Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TG Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Liabilities274.5 K260.8 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for TGTX Stock Analysis

When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.